Syndax Pharmaceuticals SNDX
- Market cap
- $1.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $289.7M
- +160% on a year ago
- Net margin
- −87.5%
- Free cash flow yield
- n/m
- not a meaningful number
Syndax Pharmaceuticals trades at 4.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $289.7M over the last twelve months, up 160% on a year earlier with a −88% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $3.5M | $12.5M | $7.7M | $20M | $38M+985% | $45.9M+267% | $68.7M+795% | $64.9M+224% | $72.8M+92% | $83.3M+82% | |
| R&D | $55.1M+73% | $56.5M+66% | $48.7M+40% | $71M+82% | $65.5M+19% | $61.6M+9% | $62.2M+28% | $56.3M−21% | $78.6M+20% | $58.8M−5% | $68M+9% | $67.5M+20% |
| SG&A | $22.8M+124% | $23M+93% | $29.1M+95% | $31.1M+80% | $37.7M+66% | $41M+78% | $43.8M+51% | $44.9M+44% | $49.9M+33% | $37.6M−8% | $41.5M−5% | $43.7M−3% |
| −$77.9M+85% | −$79.5M+73% | −$74.2M+49% | −$89.6M+59% | −$96.4M+24% | −$83.8M+5% | −$69.4M−7% | −$57.4M−36% | −$62.5M−35% | −$34.2M−59% | −$40M−42% | −$41.9M−27% | |
| Interest expense | $63K+47% | $55K+38% | $45K+29% | $23K−67% | $4.8M+7529% | $2K−96% | $4K−91% | $0 | $0 | $0 | $2K−50% | $2K |
| Net income | −$72.5M+85% | −$72.4M+76% | −$68.1M+53% | −$84.1M+65% | −$94.2M+30% | −$84.8M+17% | −$71.8M+6% | −$60.7M−28% | −$68M−28% | −$42.7M−50% | −$49.4M−31% | −$49.4M−19% |
| −$1.00+61% | −$0.85+44% | −$0.80+25% | −$0.98+34% | −$1.09+9% | −$0.98+15% | −$0.83+4% | −$0.70−29% | −$0.78−28% | −$0.48−51% | −$0.55−34% | −$0.55−21% | |
| 72.5M+15% | 85.2M+23% | 85.3M+23% | 85.4M+22% | 86.6M+19% | 86.2M+1% | 86.3M+1% | 86.6M+1% | 86.9M+0% | 88.3M+2% | 89M+3% | 89.8M+4% |
Revenue: Q1 FY15: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY21: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Syndax Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SNDXSyndax Pharmaceuticals | $1.2B | n/m | 65.8× | 4.6× | +160% | −87.5% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.6B | 15.0× | 57.5× | 1.7× | +31% | 11.1% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| HRMYHarmony Biosciences | $2.2B | 12.3× | 13.8× | 2.3× | +24% | 18.9% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| Peer median | $1.3B | 13.7× | 19.8× | 1.8× | +17% | 10.9% |
More on Syndax Pharmaceuticals
Each number over time
Where it ranks
- #8of 340Healthcare stocks with the fastest revenue growth
- #4of 97Large drugmakers with the fastest revenue growth
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .